News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug interactions and pharmacokinetics news

Show

From To
HIV treatment in children
Nevirapine dose escalation for children may risk treatment failure

Full-dose nevirapine should be considered for HIV-positive children under two years of age in Africa, to simplify ART initiation and reduce the risk of suboptimal dosing, researchers reporting

Published
03 June 2013
By
Carole Leach-Lemens
New and experimental HIV treatments
Nanoparticles May Transport HIV Meds to the Brain

Researchers have had early success in a method that might one day thwart the powerful blood-brain barrier and effectively deliver antiretrovirals to the brain.

Published
16 May 2013
From
AIDSMeds
New and experimental HIV treatments
Protease Inhibitors Boost Levels of Cenicriviroc, a CCR5/CCR2 Antagonist

Ritonavir, darunavir/ritonavir, and atazanavir/ritonavir all more than tripled exposure of cenicriviroc, an investigational CCR5 and CCR2 receptor antagonist, in 60 healthy volunteers. There were no serious or unexpected adverse events in these 20-day studies.

Published
14 May 2013
From
NATAP
Drug interactions and pharmacokinetics
Changes to label for Atripla tablets

FDA recently approved changes to the Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) tablet label to include the following changes: Lists Stribild as one of the drugs that should not be coadministered with Atripla; Adds drug interaction information for raltegravir, boceprevir and telaprevir.

Published
18 April 2013
From
FDA
Drug interactions and pharmacokinetics
Concentrations of HIV protease inhibitors increase with age

Plasma concentrations of protease inhibitors increase with age, investigators from the United Kingdom report in the Journal of Antimicrobial Chemotherapy. Each ten-year increment in age was associated with

Published
05 April 2013
By
Michael Carter
TB treatment
Dosing of key TB drug rifampicin could go higher

Rifampicin, a key drug in tuberculosis (TB) treatment, can be tolerated at much higher doses than used in current clinical practice – suggesting that much higher drug

Published
07 March 2013
By
Keith Alcorn
Drug interactions and pharmacokinetics
Prezista (darunavir) label change - drug interaction information

The FDA recently approved changes to the Prezista (darunavir) label to reflect drug interaction information with artemether/lumefantrine. The specific changes are outlined below.

Published
02 March 2013
From
US Food and Drug Administration
Treatment guidelines
Updated HIV Treatment Guidelines Include Stronger Recommendation for Acute Infection

Among the key changes are additional information about the most recently approved antiretroviral agents and a recommendation that newly infected people with HIV should be offered combination ART. The guidelines continue to recommend treatment for all people with HIV, both to reduce the risk of disease progressionand for the prevention of HIV transmission.

Published
15 February 2013
From
HIVandHepatitis.com
Hepatitis C treatment side-effects
Drug interaction warning for hepatitis C: serious side effects when using telaprevir and bosentan

A medical team in Paris, France, has reported an unexpected and disturbing drug interaction between a drug used to treat pulmonary arterial hypertension—bosentan (Tracleer)—and the HCV drug telaprevir. The interaction led to serious side effects.

Published
15 February 2013
From
CATIE
Hepatitis C treatment side-effects
Copy of Drug interaction warning for hepatitis C: serious side effects when using telaprevir and bosentan

A medical team in Paris, France, has reported an unexpected and disturbing drug interaction between a drug used to treat pulmonary arterial hypertension—bosentan (Tracleer)—and the HCV drug telaprevir. The interaction led to serious side effects.

Published
15 February 2013
From
CATIE
← First12345...15Next →

Filter by country